Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
- Regenxbio Inc (NASDAQ: RGNX) has reported additional interim data from Cohorts 4 and 5 of its Phase 1/2a trial evaluating RGX-314 for the treatment of wet age-related macular degeneration (wet AMD) and Cohort 3 of its Long-Term Follow-Up (LTFU) study.
- As of January 22, RGX-314 continued to be generally well-tolerated across all cohorts, with 20 serious adverse events (SAEs) reported in 13 patients, including one possibly drug-related SAE of a significant decrease in vision in Cohort 5.
- Patients in Cohorts 4 and 5 at 1.5 years after administration of RGX-314 demonstrated stable visual acuity and decreased central retinal thickness (CRT).
- A meaningful reduction in anti-VEGF treatment burden was observed in both Cohorts 4 and 5 compared to the mean annualized injection rate during the 12 months before RGX-314 administration.
- Patients in Cohort 4 and Cohort 5 received a mean of 4.4 injections and 1.7 injections over 1.5 years following administration of RGX-314, a 58.3% and 81.2% reduction in anti-VEGF treatment burden, respectively.
- Following the Phase 1/2a trial, patients can enroll in a long-term study to assess the safety and efficacy up to five years after RGX-314 administration.
- All six patients from Cohort 3 of the Phase 1/2a trial enrolled in the LTFU study and demonstrated a mean BCVA improvement of +12 letters from baseline at three years.
- Patients also demonstrated long-term reductions in anti-VEGF treatment burden over three years with a mean annualized rate of 2.4 anti-VEGF injections, a 66.7% reduction.
- Price Action: RGNX stock closed 0.8% lower at $46.96 on Friday.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!